Calla® 1452 Disinfection Data

Test Method: AOAC Use Dilution

Test Conditions: 5% organic soil load, 10 minute contact time, stainless steel carrier substrates, 400 ppm hard water, 20°C exposure temperature, and 4 oz per gallon dilution.

Results:

Conclusions: Under the conditions of this investigation, Calla^® 1452 demonstrated disinfectant activity against Staphylococcus aureus, Salmonella (choleraesuis) enterica, Pseudomonas aeruginosa PRD-10, Ampicillin resistant Acinetobacter baumannii, Bactrim resistant Acinetobacter baumannii, Bordetella bronchiseptica, Cefazolin resistant Acinetobacter baumannii, Ceftazdime resistant Acinetobacter baumannii, Ceftriaxone resistant Acinetobacter baumannii, Ciprofloxacin resistant Acinetobacter baumannii, Community Associated Methicillin Resistant Staphylococcus aureus (CAMRSA) (NRS 123, Genotype USA400), Community Associated Methicillin Resistant Staphylococcus aureus (CA-MRSA) (NRS384, Genotype USA300), Corynebacterium ammoniagenes, Enterobacter aerogenes, Enterobacter cloacae, Enterococcus faecalis, Escherichia coli, Fusobacterium necrophorum, Gentamicin resistant Acinetobacter baumannii, Levofloxacin resistant Acinetobacter baumannii, Klebsiella pneumonia subsp. pneumoniae, Lactobacillus casei subsp. rhamnosus, Listeria monocytogenes, Methicillin Resistant Staphylococcus aureus (MRSA), Pasteurella multocida, Proteus mirabilis (ATCC 9921), Proteus mirabilis (ATCC 25933), Proteus vulgaris, Salmonella (paratyphi B) enterica, Salmonella (pullorum) enterica, Salmonella (typhi) enterica, Salmonella (typhimurium) enterica, Salmonella (enteritidis) enterica, Serratia marcescens, Shigella dysenteriae, Shigella flexneri Type 2b, Shigella sonnei, Staphylococcus aureus subsp. aureus, Staphylococcus epidermidis, Streptococcus pyogenes Group A, Streptococcus pyogenes (clinical flesh eating strain, BIRD M3), Tobramycin resistant Acinetobacter baumannii, Vancomycin Resistant Enterococcus faecalis (VRE), and Vancomycin Intermediate Resistant Staphylococcus aureus (VISA), according to criteria established by the U.S. Environmental Protection Agency for registration and labeling of a disinfectant product as a bactericide.

Calla^® 1452 also demonstrated disinfectant activity against the following antibiotic resistant clinical isolates: Enterobacter cloacae, Enterococcus faecalis, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Xanthamonas maltophilia. At a dilution ratio of 1:13.5 (2000 ppm active quaternary), Calla^® 1452 demonstrated disinfectant activity against Xanthomonas axonopodis pathovar citri (Citrus Canker Disease).